Bend Research, Inc.

Pfizer Corporation

The Coca-Cola Company

Roderick Jack Ray

Dwayne Thomas Friesen

David D Newbold

Scott B McCray

Ronald Arthur Beyerinck

Dana Marie Settell

Dan E Dobry

Leah Elizabeth Appel

Ken R Spence

James William West

Marshall David Crew

Heather L M Deibele

David Keith Lyon

Adam S Carroll

Daniel Elmont Dobry

Daniel J Brose

Paul Van Eikeren

Brandon John Downey

Joshua R Shockey

Robert P Barss

Lisa J Graham

Kendall R Pearson

Delores R Sidwell

Heather L M Diebele

Ravi Mysore Shanker

Walter Christian Babcock

Scott Max Herbig

Daniel Tod Smithey

Julian B Lo

Guillermo A Iacobucci

Kevin Douglas Grove

Richard W Schofield

Sheri L Shamblin

Lori A Ray

Heather Lynn Deibele

Kenny Ray Spence

Heather Lynn Melcher Deibele

The present disclosure is directed to systems and methods for sampling and/or controlling the productivity of a bioreactor. The system and methods can include a vessel capable of providing an environment suitable for containing whole broth that can produce the bioproduct, wherein the whole broth contains media and at least one undissolved species, an automated sampling system, a first analytical instrument, and a control system.

Systems and methods for producing bioproducts

The present disclosure is directed to systems and methods for sampling and/or controlling the productivity of a bioreactor.

Spray drying processes are used to form pharmaceutical compositions comprising a solid amorphous dispersion of a drug and a polymer.

Spray drying processes for forming solid amorphous dispersions of drugs and polymers

A dosage form comprises a low-solubility drug, and a precipitation-inhibiting polymer. The drug is in a solubility-improved form and in the form of particles at least partially coated with the precipitation-inhibiting polymer.

Pharmaceutical dosage forms comprising a low-solubility drug and a polymer

Conventional spray-drying methods are improved by incorporation of a pressure nozzle and a diffuser plate to improve the flow of drying gas and a drying chamber extension to increase drying time, such improvements leading to the formation of homogeneous solid dispersions of drugs in concentration-enhancing polymers.

Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus

A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes, the secondary drying process utilizing a combination of vacuum, agitation, and a stripping gas.

Drying of drug-containing particles

A process for forming drug multiparticulates having improved drug crystallinity is disclosed, comprising modifying a conventional melt-congeal process by adding a volatile cospecies either to the molten mixture or to the process atmosphere, or to both.

Method of making pharmaceutical multiparticulates

A multiparticulate for controlled release of a drug comprises crystalline drug, a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a poloxamer, wherein at least 70 wt % of the drug in the multiparticulate is crystalline.

Multiparticulate crystalline drug compositions having controlled release profiles

Homogeneous solid amorphous dispersions of drugs in concentration-enhancing polymers are formed in desirable larger particle sizes with minimal fines by using an atomizer and process conditions capable of producing droplets having an average diameter of at least 50 microns and a Dof at least 10 microns.

Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles

A process is described for producing drug-containing multiparticulates with improved stability, characterized by an improvement in one or more of chemical stability, physical stability, or dissolution stability.

Multiparticulate compositions with improved stability

Reduced levels of drug degradation in drug-containing multiparticulates are obtained by an extrusion/melt-congeal process.

Extrusion process for forming chemically stable drug multiparticulates

Solvent-resistant polybenzimidazole membranes, methods of making them and crosslinking them and composite membranes and hollow fiber membrane modules from them are disclosed.

Solvent-resistant microporous polybenzimidazole membranes and modules

Growing community of inventors

Bend, OR, United States of America

Roderick Jack Ray